Detecting minimal residual disease in neuroblastoma patients-the present state of the art.
While cyto- and histological screening of bone marrow samples are still accepted as the gold standard for initial staging of neuroblastoma patients, these applications are insufficient during or after therapy because it is not always possible to detect tumour cell infiltration below the level of 1% by morphology alone. For monitoring of minimal residual disease, techniques offering a considerably higher sensitivity have been developed. Immunocytology, RT-PCR and flow cytometry are most frequently used, but differ with regard to targets (single cells, RNA transcripts), measured parameters (tumour cell number, antigen expression, cytomorphology, cytogenetic aberrations, level/number of RNA transcripts), specificity (uni-/multi-parameter analysis) and sensitivity (number of investigated cells). The pros and cons of these methods are reviewed. Precise quantification of residual tumour cells in bone marrow and blood may show a future impact on risk grouping and therapeutic strategies for patients with disseminated disease, but the potential clinical application of these techniques has to be preceded by thorough standardisation and validation in multi-centre studies.
Beiske
Klaus
K
Department of Pathology, Rikshospitalet, Sognsvannsveien 23, N-0027 Oslo, Norway. klaus.beiske@labmed.uio.no
Ambros
Peter F
PF
Burchill
Susan A
SA
Cheung
Irene Y
IY
Swerts
Katrien
K
D005434:Flow Cytometry; D006801:Humans; D018365:Neoplasm, Residual; D009360:Neoplastic Cells, Circulating; D009447:Neuroblastoma / Q000175:diagnosis / Q000473:pathology*; D020133:Reverse Transcriptase Polymerase Chain Reaction